Tulane Cancer Center and Tulane University announce the third annual

CALL FOR ABSTRACTS
Third Annual
Mauvernay Research Excellence Award Seminar
to be held November 4, 2005

Abstract Deadline: Monday, August 1, 2005

About the Award:

Tulane University, with support from Debiopharm S.A., a Swiss drug development company, has established The Mauvernay Research Excellence Fund to foster the discovery of new therapeutic agents for cancer treatment. The Fund sponsors an annual award and educational seminar as a forum for the exchange of ideas and cutting-edge information on the latest research accomplishments at Tulane that may lead to targets for cancer drug discovery and/or candidates for therapeutic use.

The Third Annual Mauvernay Research Excellence Seminar and Award Presentation will be held in Room 111A (first-floor conference room) of the J. Bennett Johnston Building on November 4, 2005. In conjunction with this seminar, the US $5,000 Mauvernay Research Excellence Award and etched crystal tribute will be presented to a member of the Tulane faculty to recognize and honor outstanding and innovative research identifying targets for cancer drug discovery and/or candidates for therapeutic use.

Guidelines: Abstract due date: Monday, August 1, 2005

The application and abstract form is downloadable here in MS-Word format. It can also be obtained by contacting:
Melanie Cross, Tulane Cancer Center
Campus Box SL-68
1430 Tulane Ave., New Orleans, LA, 70112
504-988-6592, mcross@tulane.edu
Interested Tulane faculty members should submit an application packet containing each of the following:

1. Ten copies of the completed application and abstract form, which provides space for:
   • A 200-word paragraph in layman's terms on how your research can lead to discovering targets for potential anti-cancer drugs and/or candidates for therapeutic use, and
   • A scientific abstract of 500 words or fewer
     (Abstracts should include title of work, names and affiliations (Department/School/Center) of principal investigator and all co-authors, overall objectives, research methods, results obtained, discussion of the significance of the results, and conclusion(s). Abstracts will be published in a meeting brochure and can include previously published data, provided the focus is on targets for potential drugs.)
2. Ten copies each of two supporting publications
3. Ten copies of an NIH bio sketch
4. Ten copies of a list of current active research funding

The complete application packets must be received by the due date (Monday, August 1, 2005) in the office of:
Melanie Cross, Tulane Cancer Center
J. Bennett Johnston Building, Mezzanine, Suite A102
Campus Box SL-68
1430 Tulane Ave., New Orleans, LA, 70112

Abstracts will be reviewed by an external jury. After reviewing all submitted abstracts, the jury will name the Mauvernay Lecturer and Research Excellence Scholar, who will receive an etched crystal tribute and a cash prize of US $5,000. The Mauvernay Scholar will also be the featured speaker at The Third Annual Mauvernay Research Excellence Seminar, November 4, 2005. The jury will also select up to 10 additional abstracts to receive Awards of Excellence. These awards consist of a US $500 cash prize and presentation of data in poster format at The Mauvernay Research Excellence Seminar, November 4, 2005.

This page is http://www.som.tulane.edu/cancer/mauvernaycall.html
This page was last updated on

---

Return to the top of this page.
Return to the Tulane Cancer Center homepage.

Calendars Clinical Trials Faculty Links Location News

Search Site index
See also: listing of Research Grants and Funding Opportunities

---

Tulane Cancer Center, Box SL-68
1430 Tulane Avenue
New Orleans, Louisiana 70112-2699
(504) 988-6060, fax (504) 988-6077
http://www.som.tulane.edu/cancer